246 related articles for article (PubMed ID: 38300479)
21. BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor.
Sahnane N; Carnevali I; Formenti G; Casarin J; Facchi S; Bombelli R; Di Lauro E; Memoli D; Salvati A; Rizzo F; Sessa F; Tibiletti MG
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352687
[TBL] [Abstract][Full Text] [Related]
22. Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CAncer Gene-mutated ovarian tumours: definition of homologous recombination deficiency?
Gourley C; Miller RE; Hollis RL; Ledermann JA
Curr Opin Oncol; 2020 Sep; 32(5):442-450. PubMed ID: 32796232
[TBL] [Abstract][Full Text] [Related]
23. A comprehensive literature review and meta-analysis of the prevalence of pan-cancer BRCA mutations, homologous recombination repair gene mutations, and homologous recombination deficiencies.
Shao C; Wan J; Lam FC; Tang H; Marley AR; Song Y; Miller C; Brown M; Han J; Adeboyeje G
Environ Mol Mutagen; 2022 Jul; 63(6):308-316. PubMed ID: 36054589
[TBL] [Abstract][Full Text] [Related]
24. Homologous Recombination Deficiency Landscape of Breast Cancers and Real-World Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Patients With Somatic
Batalini F; Madison RW; Sokol ES; Jin DX; Chen KT; Decker B; Pavlick DC; Frampton GM; Wulf GM; Garber JE; Oxnard G; Schrock AB; Tung NM
JCO Precis Oncol; 2023 Sep; 7():e2300091. PubMed ID: 37992259
[TBL] [Abstract][Full Text] [Related]
25. The effect of PARP inhibitors in homologous recombination proficient ovarian cancer: meta-analysis.
Skelin M; Šarčević D; Lešin Gaćina D; Mucalo I; Dilber I; Javor E
J Chemother; 2023 Apr; 35(2):150-157. PubMed ID: 35550005
[TBL] [Abstract][Full Text] [Related]
26. U.S. Food and Drug Administration-Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer: A Cost-Effectiveness Analysis.
Dottino JA; Moss HA; Lu KH; Secord AA; Havrilesky LJ
Obstet Gynecol; 2019 Apr; 133(4):795-802. PubMed ID: 30870286
[TBL] [Abstract][Full Text] [Related]
27. Genomic Determinants of Homologous Recombination Deficiency across Human Cancers.
Qing T; Wang X; Jun T; Ding L; Pusztai L; Huang KL
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572800
[TBL] [Abstract][Full Text] [Related]
28. PARP inhibitors for BRCA wild type ovarian cancer; gene alterations, homologous recombination deficiency and combination therapy.
Matsumoto K; Nishimura M; Onoe T; Sakai H; Urakawa Y; Onda T; Yaegashi N
Jpn J Clin Oncol; 2019 Aug; 49(8):703-707. PubMed ID: 31242303
[TBL] [Abstract][Full Text] [Related]
29. European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer.
Vergote I; González-Martín A; Ray-Coquard I; Harter P; Colombo N; Pujol P; Lorusso D; Mirza MR; Brasiuniene B; Madry R; Brenton JD; Ausems MGEM; Büttner R; Lambrechts D;
Ann Oncol; 2022 Mar; 33(3):276-287. PubMed ID: 34861371
[TBL] [Abstract][Full Text] [Related]
30. An activity-based functional test for identifying homologous recombination deficiencies across cancer types in real time.
Lee CY; Cheng WF; Lin PH; Chen YL; Huang SH; Lei KH; Chang KY; Ko MY; Chi P
Cell Rep Med; 2023 Nov; 4(11):101247. PubMed ID: 37863059
[TBL] [Abstract][Full Text] [Related]
31. Homologous Recombination Deficiency and Ovarian Cancer Treatment Decisions: Practical Implications for Pathologists for Tumor Typing and Reporting.
Rabban JT; Chen LM; Devine WP
Surg Pathol Clin; 2022 Jun; 15(2):219-234. PubMed ID: 35715159
[TBL] [Abstract][Full Text] [Related]
32. Cost-Effectiveness Analysis of Biomarker Testing to Guide First-Line PARP Inhibitor Maintenance for Patients with Advanced Ovarian Cancer After Response to First-Line Platinum Chemotherapy in the USA.
Elsea D; Muston D; Fan L; Mihai A; Meng Y; Kasle A; Monberg M
Target Oncol; 2023 Jul; 18(4):531-541. PubMed ID: 37233868
[TBL] [Abstract][Full Text] [Related]
33. BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer.
Moschetta M; George A; Kaye SB; Banerjee S
Ann Oncol; 2016 Aug; 27(8):1449-55. PubMed ID: 27037296
[TBL] [Abstract][Full Text] [Related]
34. Antitumor efficacy of PARP inhibitors in homologous recombination deficient carcinomas.
Yi T; Feng Y; Sundaram R; Tie Y; Zheng H; Qian Y; You D; Yi T; Wang P; Zhao X
Int J Cancer; 2019 Sep; 145(5):1209-1220. PubMed ID: 30666631
[TBL] [Abstract][Full Text] [Related]
35. Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literature.
Frey MK; Pothuri B
Gynecol Oncol Res Pract; 2017; 4():4. PubMed ID: 28250960
[TBL] [Abstract][Full Text] [Related]
36. Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA Mutations.
Xu Q; Li Z
Front Pharmacol; 2021; 12():743073. PubMed ID: 34912215
[TBL] [Abstract][Full Text] [Related]
37. Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor.
Tymon-Rosario JR; Manara P; Manavella DD; Bellone S; Hartwich TMP; Harold J; Yang-Hartwich Y; Zipponi M; Choi J; Jeong K; Mutlu L; Yang K; Altwerger G; Menderes G; Ratner E; Huang GS; Clark M; Andikyan V; Azodi M; Schwartz PE; Alexandrov LB; Santin AD
Gynecol Oncol; 2022 Jul; 166(1):117-125. PubMed ID: 35599167
[TBL] [Abstract][Full Text] [Related]
38. Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy.
Sheta R; Bachvarova M; Plante M; Renaud MC; Sebastianelli A; Gregoire J; Navarro JM; Perez RB; Masson JY; Bachvarov D
J Transl Med; 2020 Nov; 18(1):439. PubMed ID: 33213473
[TBL] [Abstract][Full Text] [Related]
39. Simple prediction model for homologous recombination deficiency in breast cancers in adolescents and young adults.
Watanabe T; Honda T; Totsuka H; Yoshida M; Tanioka M; Shiraishi K; Shimada Y; Arai E; Ushiama M; Tamura K; Yoshida T; Kanai Y; Kohno T
Breast Cancer Res Treat; 2020 Jul; 182(2):491-502. PubMed ID: 32488393
[TBL] [Abstract][Full Text] [Related]
40. BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors.
Petrelli A; Rizzolio S; Pietrantonio F; Bellomo SE; Benelli M; De Cecco L; Romagnoli D; Berrino E; Orrù C; Ribisi S; Moya-Rull D; Migliore C; Conticelli D; Maina IM; Puliga E; Serra V; Pellegrino B; Llop-Guevara A; Musolino A; Siena S; Sartore-Bianchi A; Prisciandaro M; Morano F; Antista M; Fumagalli U; De Manzoni G; Degiuli M; Baiocchi GL; Amisano MF; Ferrero A; Marchiò C; Corso S; Giordano S
Cancer Res; 2023 May; 83(10):1699-1710. PubMed ID: 37129948
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
